Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy

Annals of Clinical Biochemistry

Volumn 46, Issue 5, 2009, Pages 407-412

  Fulton, Richard B ^a   Fernando, Suran L ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN;

ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ELECTROPHORESIS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SERUM FREE LIGHT CHAIN ASSAY; URINALYSIS;

ELECTROPHORESIS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; PARAPROTEINEMIAS; REPRODUCIBILITY OF RESULTS;

EID: 69749124830     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2009.009038     Document Type: Article

References (27)

1. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-680
2. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-491
3. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2902
4. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119:274-278
5. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473 (Pubitemid 44264086)
6. Nowrousian MR, Brandhorst D, Daniels R, et al. Free light chain measurement in serum compared with immunofixation of urine in patients with multiple myeloma. Blood 2003;102:5197a
7. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2003;49:74a
8. Katzmann JA, Dispenzieri A, Kyle RA, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using sIFE and free light chain assays. Mayo Clin Proc 2006;81:1575-1578 (Pubitemid 44871901)
9. Hill PG, Forsyth JM, Rai B, Mayne S. SFLCs: an alternative to the urine BJPs screening test for monoclonal gammopathies. Clin Chem 2006;52:1743-1748
10. Rajkumar SV, Kyle RA, Therneau TM, et al. Presence of an abnormal serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood 2005;104:3647
11. Piehler AP, Gulbrandsen N, Kierulf P, Urdal P. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem 2008;54:1823-1830
12. Pratt G. The evolving use of sFLC assays in haematology. Br J Haematol 2008;141:413-422
13. Nowrousian MR, Brandhorst D, Sammet C, et al. SFLC analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005;11:8706-8714 (Pubitemid 43005920)
14. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative and free light chain assays in clinical practice. Clin Chem 2005;51:878-881 (Pubitemid 40577925)
15. Bradwell AR. SFLC Analysis. Birmingham: The Binding Site Ltd, 2006
16. Tate JR, Devinder G, Cobcroft R, Hickman PE. Practical considerations for the measurement of free light chains in serum. Clin Chem 2003;49:1252-1257 (Pubitemid 36900609)
17. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light chain diseases. Clin Chim Acta 2007;376:30-36 (Pubitemid 44880976)
18. Jaskowski TD, Litwin CM, Hill HR. Detection of and light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis. Clin Vaccine Immunol 2006;13:277-280
19. Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest 1972;51:2162-2164
20. 131I) Bence Jones protein catabolism in human subjects. Clin Chim Acta 1967;18:395-407
21. Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med 1967;126:207-221
22. Bradwell AR, Evans ED, Chappell MJ, et al. Rapid removal of free light chains from serum by hemodialysis for patients with myeloma kidney. Blood 2005;106:972a
23. Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chains as a marker of response. Blood 2008;111:4908-4915
24. Singhai S, Stein R, Vickrey E, Mehat J. The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood 2007;109:3611-3612 (Pubitemid 46572562)
25. Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002;48:655-657
26. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994;53:207-212
27. Katzmann JA, Dispenzieri A. Screening algorithms for monoclonal gammopathies. Clin Chem 2008;54:1753-1755